Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ Myeloid Dendritic Cells in NSCLC Subtitle v3.0: A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ Myeloid Dendritic Cells in Solid Tumors.
Conditions
Interventions
Avelumab
Ipilimumab 5 MG/ML
+2 more
Locations
2
Belgium
Universitair Ziekenhuis Brussel
Jette, Brussels Capital, Belgium
Uz Brussel
Brussels, Belgium
Start Date
September 22, 2020
Primary Completion Date
December 1, 2023
Completion Date
December 1, 2023
Last Updated
September 14, 2022
NCT06132828
NCT04570423
NCT06144671
NCT06926283
NCT05671510
NCT07489378
Lead Sponsor
Universitair Ziekenhuis Brussel
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions